Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A

Samankaltaisia teoksia

• Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphisms in the HMOX1 promoter
  Tekijä: Repessé, Yohann, et al.
  Julkaistu: (2013)
• Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity
  Tekijä: Oldenburg, Johannes, et al.
  Julkaistu: (2015)
• Maternally transferred anti-factor VIII IgG reduce the anti-factor VIII humoral immune response in factor VIII-deficient mice
  Tekijä: Meslier, Yann, et al.
  Julkaistu: (2010)
• Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A
  Tekijä: Calvez, Thierry, et al.
  Julkaistu: (2018)
• High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis
  Tekijä: Messori, Andrea, et al.
  Julkaistu: (2018)